Not exact matches
With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their
efforts on planning clinical trials
in immunotherapy, recruit patients quickly, and share the information learned — which could be the single biggest factor
in speeding up
drug development.
But rather than buying up a genetic research outfit, it decided to build its own
in the form of the Regeneron Genetics Center (RGC), an ambitious four - year old
effort to sequence as many exomes (the protein - encoding part of the genome) as possible, pair them with medical records, and accelerate
drug development.
The SAMSHA grant, totaling $ 971,736 over a three - year period, will also support personnel, training and other needs related to the
development of a peer mentor initiative to help military veterans enrolled
in the County's
drug treatment court programs re-adjust to civilian life and get back on track, as well as
efforts to increase participation rates
in court - mandated treatment programs among justice - involved veterans.
Another example, he said, is the National Cancer Institute's
drug formulary launched
in 2017 that helps researchers quickly access commercial cancer
drugs under
development, to test promising
drug combinations
in clinical trials, an
effort made possible after difficult issues of intellectual property, access and licensing were worked out.
But, as Anne - Catrin Uhlemann and David Fidock
in an essay
in the same issue of The Lancet wrote, «
drug development efforts are not expected to yield new antimalarials until the end of this decade.»
We are making
efforts to apply these findings
in the
development of
drugs against viruses such as human parainfluenza virus,» Professor Sakaguchi described.
Unsurprisingly, then, MET is the target of a number of
drug development efforts, which have
in common the aim of blocking MET's activation.
The work published
in Cancer Cell complements previous research
efforts from the CNIO Melanoma Group, which could lead to the
development of novel
drugs that selectively target the mechanism of cell autodigestion as a potential therapeutic strategy.
«If modifying cholesterol levels
in the brain early
in life turns out to reduce amyloid deposits late
in life, we could potentially make a significant difference
in reducing the prevalence of Alzheimer's, a goal of an enormous amount of research and
drug development effort.»
Drug development efforts based on harmine will need to grapple with its known psychoactive effects on the brain, which may explain its traditional use
in spiritual ceremonies and as medicine.
Since then, much
effort has been focused on identifying these genes
in the hopes that they could potentially become
drug development targets.
Among these deaths are many that could be prevented by concentrated
efforts in the research,
development and distribution of new
drugs.
Additional genes included
in the database could be the focus of future
drug development efforts because they belong to classes of genes that are thought to make promising
drug targets.
In early
drug development efforts, Longmore and his colleagues have done some preliminary work looking for small molecules that may inhibit DDR2 binding to collagen.
The expert group was convened through the Alzheimer's Association Research Roundtable — an ongoing
effort that brings together experts
in the field from academia, industry, and government to address ways to overcome barriers to
drug development.
The authors call for the
development of clinical guidelines to support physicians
in their
effort to reduce potentially futile
drug treatments near the end of life.
Founded
in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for Spinal Muscular Atrophy through targeted funding of clinical research and novel
drug development efforts.
Families of SMA applauds ISIS for investing
in and leading
drug developments efforts for this devastating, orphan disease.»
Under the alliance, deCODE and Merck will combine their cutting - edge research
efforts in the genetics of obesity to identify, validate and prioritize a series of
drug targets to take into
development.
About the SMA Foundation Founded
in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel
drug development efforts.
This
effort will combine academic groundbreaking discoveries with
drug discovery expertise and
development traditionally only found
in the pharmaceutical industry.
ANN ARBOR, Mich. — Sept. 15, 2008 — Assay Designs and the Spinal Muscular Atrophy Foundation (SMAF) are very pleased to announce a collaborative agreement for
development of reagents and assays for SMN (Survival Motor Neuron) protein to expedite
drug discovery and
development efforts for spinal muscular atrophy (SMA), the leading genetic cause of mortality
in infants and toddlers.
About the Spinal Muscular Atrophy Foundation Founded
in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel
drug development efforts.
Founded
in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel
drug development efforts.
In any
drug development effort, the first goal has to be ensuring the
drug doesn't have toxic side effects.
The new advisors, some of the most wellrespected individuals
in their fields, were specifically sought for the wealth of experience they bring to bear on Foundation
efforts to advance
drug development in SMA: Paul S. Anderson, PhD, retired vice president for Chemistry at Merck, G. Stephen DeCherney, MD, MPH, president of Clinical Development Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of Texas
development in SMA: Paul S. Anderson, PhD, retired vice president for Chemistry at Merck, G. Stephen DeCherney, MD, MPH, president of Clinical
Development Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of Texas
Development Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment
effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of Texas at Austin.
Founded
in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for spinal muscular atrophy through targeted funding of clinical research and novel
drug development efforts.
Founded
in 2003, the SMA Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for Spinal Muscular Atrophy (SMA) through targeted funding of clinical research and novel
drug development efforts.
Our
efforts are heavily focused on studies and projects that culminate
in essential research tools and data that can drive novel
drug development forward.
About The SMA Foundation Founded
in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel
drug development efforts.
Jeff Gulcher, deCODE's VP of Research and
Development, added: «deCODE will continue to deliver important findings to Roche to aid in their drug development and diagnost
Development, added: «deCODE will continue to deliver important findings to Roche to aid
in their
drug development and diagnost
development and diagnostic
efforts.
This Hub will ensure Australia does not miss out on advances
in genomic - driven advances
in drug development and oncology, and will lay the foundations for advances
in the global
effort to transform cancer research and treatment.
Despite ongoing
efforts toward finding novel entities for the treatment of the most challenging cancers, translation into patient benefit has been slow due to the fact that translational cancer research from early
drug discovery to late stage
drug development and assessment
in clinical trials is a long process.
«Our intellectual property portfolio is advancing
in parallel with our AV411
development efforts for pain states and certain
drug addiction conditions, thus creating a cohesive program.»
Jointly published by WHO, the United Nations
Development Programme, and the United Nations Office on
Drugs and Crime, the report reviews the current status of violence prevention
efforts in countries, and calls for a scaling up of violence prevention programmes; stronger legislation and enforcement of laws relevant for violence prevention; and enhanced services for victims of violence.